tirzepatide/glycine/b12 strive Altrx : r/tirzepatidecompound Tirzepatide/B12 10mg/500mcg/1ml -6 ml via

Wet (Neovascular / Exudative) Macular Degeneration Prevalence: ~1015% of AMD cases Pathophysiology: Abnormal choroidal neovascularization (CNV) under macula Leakage hemorrhage, exudation rapid central vision loss Clinical Features: Sudden or rapid decrease in central vision Metamorphopsia (straight lines appear wavy) Central scotomas May have subretinal hemorrhage Progression: rapid severe central vision loss if untreated Management: Intravitreal anti-VEGF injections (ranibizumab, bevacizumab, aflibercept) Laser photocoagulation (rarely, specific cases) Low-vision aids Dry AMD: slow, painless central vision loss, drusen present Wet AMD: rapid central vision loss, metamorphopsia, hemorrhage common Wet AMD is vision-threatening and requires anti-VEGF therapy Peripheral vision usually preserved in both types Summary Macular degeneration causes central vision loss

Its dual-incretin mechanism may offer enhanced metabolic benefits compared with selective GLP-1 receptor agonists such as semaglutide

Sana makes weight loss simple, safe, and science-backed

Which GLP-1 is easiest on the stomach

Decreased bone mineral density with long-term use